Review Papers Against Their Own Results

 Quick Explanation Copied

 Long Explanation

What the review claims, and how well the evidence holds up

Riedell's review (Clinical Lymphoma, Myeloma & Leukemia, 2020) synthesizes the three pivotal CD19 CAR-T trials in relapsed/refractory aggressive B-NHL: ZUMA-1 (axi-cel, CD28 co-stimulation, ORR 83%/CR 58%), JULIET (tisa-cel, 4-1BB, ORR 52%/CR 40%), and TRANSCEND (liso-cel, 4-1BB, ORR 73%/CR 53%), concluding that durable remissions occur in ~35–45% of infused patients and that relapses mostly occur within 6–12 months Riedell CAR-T review in aggressive B-NHL.

Critical appraisal

Strengths: The review is candid about what CAR-T does not do — roughly 60% of patients fail to achieve long-term remission — and honestly flags that cross-trial toxicity comparisons are confounded by differing grading scales (Lee vs Penn criteria), an inference the author explicitly labels as impression rather than data. Its discussion of real-world drift (~50% of commercial patients would have been trial-ineligible, yet outcomes appeared comparable) is well supported by the US Lymphoma CAR T Consortium analysis US Lymphoma CAR T Consortium real-world axi-cel outcomes.

Weaknesses and blind spots: (1) It is a narrative, single-author review with no systematic search method or risk-of-bias appraisal. (2) The claimed possible “cure” for some patients rests on modest ZUMA-1 long-term follow-up without mature survival curves. (3) Trial populations differ substantially (e.g., 0% vs 92% bridging therapy; 17 vs 54 day manufacturing turnaround), making the efficacy table visually striking but not a controlled comparison — the author partially acknowledges this. (4) The paper cites conference abstracts (TRANSCEND) as if peer-reviewed. (5) No conflict-of-interest or funding statement is present in the available record, which is a transparency gap for a field heavily sponsored by Kite/Gilead, Novartis, and BMS.

What has aged — and falsification status (2026 hindsight)

Several forecasts have since been validated or extended: dual CD19/CD22 targeting did enter clinical use and confirmed CD19 antigen loss as a dominant relapse mechanism CD19/CD22 bispecific CAR-T phase 1, and tumor-burden prognostication (the review's “lower tumor bulk trend”) matured into the validated CAR-IMPI index CAR-IMPI metabolic prognostic index validation. The “many patients may be cured” claim remains plausible but not proven for the majority; cure fraction estimates in randomized settings were not yet mature at publication. Confidence: moderate-to-high for the trial figures (single-arm trial data); lower for the cure claim.

 BGPT Paper Review

Study Novelty

A timely 2020 synthesis of already-published pivotal trial data; the framing around real-world eligibility drift and earlier-line trials added moderate value but no new primary data.

Scientific Quality

Accurate reporting of trial figures and honest acknowledgment of cross-trial confounding, but it is a narrative review with no systematic methodology, cites conference abstracts, and lacks a visible COI/funding statement.

Study Generality

Covers efficacy, patient selection, toxicities, resistance mechanisms, and access across the entire aggressive B-NHL CAR-T landscape, though it is disease- and product-specific.

Study Usefulness

Practically useful as a clinician-oriented snapshot of 2020 standards for patient selection and referral timing; partially superseded by later prognostic indices and bispecific products.

Study Reproducibility

Reviews aggregate published data rather than reporting original methods or datasets; nothing to reproduce beyond re-reading cited trials.

Explanatory Depth